CME GROUP INC.CME
CME GROUP INC. Financial Overview 2020–2024
CME Group functions as a high-margin toll road for global risk, converting volatility into profit with an operating margin that reached 67.5% in Q1 2025. This derivatives giant operates as a critical hedge against economic uncertainty, capitalizing on interest rate fluctuations to drive transaction fees even when equity markets stagnate. Reflecting this structural advantage, total revenue climbed from $4.88 billion in FY2020 to $6.13 billion in FY2024, anchored by its global dominance in electronic trading.
Recent performance underscores the scalability of this model, with average daily volume hitting a record 26.5 million contracts in FY2024. By the third quarter of 2025, year-to-date net income had grown 9% to $2.89 billion, supported by a lucrative market data segment that expanded 13% over the same period. Management utilizes this robust cash generation to reward shareholders, evidenced by a $3.0 billion share repurchase program authorized in FY2024. This operational leverage has fueled a steep ascent in fundamental value, with annual earnings per share growing from $5.87 in FY2020 to $9.67 at the close of FY2024.
Recent Developments (Q2 and Q3 2025)
CME experienced a distinct shift in momentum between the second and third quarters of 2025. In Q2 2025, revenue jumped 10% to $1.69 billion alongside a 15% surge in contract volume. However, reduced market volatility caused Q3 2025 revenue to slip 3% to $1.54 billion, driven by a 5% decline in clearing and transaction fees. Despite this volume contraction, the company successfully monetized its information products, with market data revenue growing 14% in the third quarter.
Operationally, management maintained discipline as expenses rose just 1% to $565 million despite ongoing cloud infrastructure investments. Bullish investors highlight the 5% increase in average rate per contract during Q3 2025 as evidence of strong pricing power. Conversely, bears argue that the valuation appears stretched at 27.9x earnings as of late October 2025, given the model's sensitivity to volatility cycles. Furthermore, the company anticipates a $300 million gain in Q4 2025 following the completed sale of its OSTTRA stake.
What to watch: capital allocation following the OSTTRA divestiture gain; volume impact from pricing changes effective February 2026.
Rev
$6.13B
FY2024
NI
$3.53B
FY2024
EPS
$9.69
FY2024
OCF
$3.69B
FY2024
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
CME GROUP INC. 8-K Report, Financial Results (Feb 4, 2026)
CME Group Inc. (CME) filed an 8-K report on February 4, 2026, announcing its financial results for the fourth quarter and full year ended December 31, 2025. The report primarily references an attached press release (Exhibit 99.1) which contains detailed financial information and commentary from the company. Investors should note that the press release includes both GAAP and non-GAAP financial measures. The non-GAAP measures, which include revenues, expenses, operating income, net income, and earnings per share, are presented to offer supplemental insights into financial and business trends and to enhance comparability with prior periods. CME Group emphasizes that these non-GAAP metrics are intended to be used in conjunction with, and not as a substitute for, GAAP-based financial reporting, and a reconciliation between the two is provided in the press release. While the 8-K itself does not contain the specific financial figures, the incorporated press release is the primary source for understanding CME Group's performance. Investors are encouraged to review Exhibit 99.1 for detailed operational and financial outcomes, including the company's commentary on its performance drivers and outlook. The filing also includes the standard cover page in Inline XBRL format.
CME GROUP INC. 8-K Report, Regulation FD Disclosure (Feb 2, 2026)
CME Group Inc. (CME) has filed a Current Report on Form 8-K dated February 2, 2026, to disclose important pricing changes communicated to its clients through Special Executive Report 9676. This announcement, made effective February 1, 2026, is being shared proactively with investors and the market, though specific details of the pricing adjustments are not included in this 8-K filing. Investors should note that this information is provided under Regulation FD Disclosure and is not deemed 'filed' for purposes of Section 18 of the Exchange Act, meaning it does not carry the same regulatory implications as a traditional filing.
CME GROUP INC. 8-K Report, Financial Results (Oct 22, 2025)
CME Group Inc. (CME) has filed an 8-K report on October 22, 2025, to disclose its financial results for the quarter ended September 30, 2025. The report primarily incorporates a press release detailing these results. Investors should note that the press release includes both GAAP and non-GAAP financial measures. Management presents these non-GAAP figures, such as revenues, expenses, operating income, net income, and earnings per share, to offer supplemental insights into the company's financial performance and business trends. These non-GAAP measures are intended to enhance comparability with prior periods and are provided alongside reconciliations to the most directly comparable GAAP figures, as required by Regulation G. The company emphasizes that these non-GAAP measures should be considered supplemental and not a substitute for GAAP reporting.
CME GROUP INC. 8-K Report, Executive Changes (Sep 11, 2025)
CME Group Inc. (CME) has filed an 8-K report announcing the upcoming retirement of its Managing Director and Chief Accounting Officer, Jack Tobin. Mr. Tobin, who has been with the company for over 23 years and served as Chief Accounting Officer since 2015, will continue in his role until October 30, 2026, ensuring a lengthy and orderly transition. His retirement is voluntary and not a result of any disputes concerning the company's financial reporting or operational matters. This transition represents a significant leadership change within CME Group's accounting function. Investors will want to monitor the company's succession planning process for this critical role, as the Chief Accounting Officer plays a key part in financial reporting integrity and strategic financial decisions. The extended transition period is a positive factor, suggesting management is prioritizing continuity and minimizing potential disruption to ongoing operations and investor confidence.
CME GROUP INC. 8-K Report, Corporate Update (Jul 25, 2025)
CME Group Inc. (CME) announced a significant legal victory on July 25, 2025, with a jury returning a unanimous verdict in its favor and that of its subsidiary, the Board of Trade of the City of Chicago, Inc. (CBOT). This ruling concludes a protracted putative class action lawsuit initiated in January 2014. The plaintiffs, comprised of certain Class B shareholders of CME Group and Class B members of CBOT, had alleged breaches of contract and the implied covenant of good faith and fair dealing related to violations of their fundamental rights as outlined in the companies' respective Certificates of Incorporation. This favorable verdict represents a material positive development for CME Group, resolving a long-standing legal dispute that could have had potential financial and operational implications. The unanimous decision by the jury strongly validates the company's position and defenses against the plaintiffs' claims. Investors should view this outcome as a de-risking event, removing a significant overhang and allowing management to maintain its full focus on strategic growth and operational execution without the distraction and potential cost of this litigation.
View all 8-K filings →